graph Evidence gap map comparisons
nivolumab based treatmentImmune checkpoint association
nivolumab alone nivolumab plus ipilimumab
Extensive stage SCLC (Es-SCLC) - maintenance (M) 2     
Comparator:  vs placebo; 
Risk of bias:  low;   some concerns;   high;  NA;